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Introduction
Substantial progress has been achieved in treating congenital 
cardiovascular diseases due to better diagnostics, advance 
surgical techniques and improvement in postoperative care. 
Nevertheless, the ultimate goal is to achieve a physiologic 
and durable repair that has the potential to grow, which has 
not been attained yet due to the limitations of all the tissue 
substitutes used. Therefore, there remains the need for 
surgical re-intervention through the patient’s lifetime. 
Aortic valve patients suffering from symptomatic aortic 
stenosis or insufficiency have limited life expectancy (1). 
Degenerative valve disease has become the most frequent 
disease leading to aortic valve replacement (AVR) in adults, 
which has been established as a standard treatment but 
implies prosthesis-related complications. Generally, the 
replacement of diseased valves is done by either mechanical 
prosthesis or bioprosthetic tissue valves. Mechanical valves 
need anticoagulation, which is contraindicated in the young 
frequently (relatively), either for planned pregnancy or 
because their lifestyle is very active. All biological valves are at 
risk for calcification and structural valve degeneration (SVD), 
leading to reoperation. The age of the patient at the time 
of valve implantation was shown to be the most important 
determinant of SVD (2); besides, it has been demonstrated 
that neonates and infants undergoing AVR are a high-risk 
group for mortality (3). All the valve prostheses used have 
the disadvantage in that they are unable to grow, repair or 
remodel, and are thrombogenic and pose an increased risk for 
endocarditis. Techniques like the Ross principle or homograft 
implantation have been introduced, especially in children and 
adolescents. Unfortunately, the rate of SVD for homograft—
around 30% after 10 years and 59% after 15 years—is similar 
to bioprosthetic valves (2). Both the Ross principle and 
homograft do not have the ability to grow, as is expected of 
an ideal valve substitute, alongside hemodynamic function 
as the original valve, non-thrombogenic, no antigenicity 
and no structural degeneration. In contrast to older patients 
suffering from degenerative valve disease, young adults and 
children face the risk of either multiple reoperations or the 
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side effect of lifelong anticoagulation. The lack of an ideal 
valve substitute has raised interest in alternative techniques, 
such as repairing the diseased valve rather than replacing it. 
In the past several years, the percentage of valve repair as 
compared to AVR has increased (1). For many of the aortic 
valve repair techniques, a patch is needed as substitute, partial 
or complete replacement or leaflet extension. So far various 
cusp tissue substitutes have been tested, but failed to fulfill 
the requirements for an optimal patch material.
Currently used patch material for valve repair
An optimal patch material should be pliable, hemostatic and 
resistant to tearing, should not shrink or calcify, and should 
possibly not induce an inflammatory cascade. Since the late 
1960s, attempts have been made to use biologic materials 
like fascia lata, dura mater and bovine pericardium with poor 
outcomes (4-6). An easily available source for valve repair is 
the autologous pericardium, which is widely used for partial 
or total cusp replacement or leaflet extension (7-10). Some 
groups propagate pretreatment with glutaraldehyde, which 
prevents secondary shrinking and calcification (9,10). On 
the other hand, untreated fresh autologous pericardium 
might possess true growth, but distensibility as well. 
Despite good short- and mid-term results, it is associated 
with a high degeneration rate in the long term (11-14) and 
is associated with bacterial endocarditis (8,10,15). Bovine 
pericardium—used as leaflet extension—has been shown 
to be less effective as compared to autologous pericardium 
(16,17), and autologous pericardium has greater resistance 
to retraction. Since polytetrafluoroethylene (PTFE) 
was successfully used for right ventricular outflow graft 
reconstruction or in mitral leaflet position with good long-
term results (18-20), it was applied as leaflet extension in 
the aortic valve position. Nosál' and coworkers reported 
13 congenitally affected patients, with the youngest being 
22 months old, in whom PTFE leaflet extensions were done 
with a follow-up till 30 months (21). However, there still 
remains a higher risk of endocarditis, and concerns have 
been raised about leaflet thickening and decreased mobility 
(18,22). Technical and scientific achievements in the field of 
tissue engineering (TE) may offer new perspectives with the 
potential of an off-the-shelf starter matrix for guided tissue 
regeneration.
Study rationale
The ultimate goal is to develop an aortic valve leaflet 
substitute which is physiological, durable and has the 
potential for growth, and test it in a chronic animal 
model. Our research group developed an off-the-shelf 
decellularized TE patch (TEP) as an aortic valve leaflet 
substitute (23,24). In a step-by-step approach, we want to 
establish an animal model as proof for feasibility, and, in 
a further step, we plan to use the chronic animal model as 
proof of concept.
For decades, different animal models have been a central 
critical component in the pre-clinical safety evaluation of 
cardiovascular devices developed for use in humans (25).
Here, we describe our technique of implantation of this 
decellularized TEP as an aortic valve leaflet substitute in a 
pre-clinical large animal model in orthotropic position.
Operative technique
We operated on adult Swiss White Mountain sheep (59–65 kg). 
All the surgical procedures and postoperative care were 
carried out in accordance with the approved protocol 
by the Ethics Committee (approval no. 19/2013) of the 
Canton (state) of Zurich. During the course of the animal 
experiments, all the animals received humane care in 
accordance with the Guide for Care and Use of Laboratory 
Animals (Publication no. 85-23. Bethesda, MD: National 
Institutes of Health, 1985) as well as with the “Principles of 
Laboratory Animal-Care”.
After general anesthesia and preoperative preparation 
(invasive blood pressure lines femoral artery and upper body 
half (ear), venous lines, bladder catheter,) either median 
sternotomy (n: 6) or right lateral thoracotomy (RLT; n: 4) 
using 4th intercostal space, without removing a rib, was 
carried out. The pericardium was opened by protecting 
the phrenic nerve and stay sutures were placed. For 
cardiopulmonary bypass (CPB), 10,000 IU of Heparin was 
given and the activated clotting time (ACT) levels above 
300 seconds were maintained throughout the CPB. Arterial 
cannulation was done via the aortic arch (n: 3) or truncus 
brachiocephalicus (n: 4) using a 21-F cannula, which allows 
adequate arterial inflow. Venous cannulation via the right 
atrium using a single stage 36-F cannula was carried out. 
A pulmonary VENT catheter was placed with continuous 
suction (150 mL/minute). Temperature monitoring was 
done with a rectal probe and mild hypothermia (32 degree 
Celsius) was sought for the intervention. Calafiore blood 
cardioplegia was given over the aortic root, followed by 
aortotomy. The aortic valve was exposed by using three stay 
sutures just above the upper edge of the commissures. The 
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non-coronary leaflet was completely explanted (see Figure 1) 
and used as a pattern for patch tailoring. The TEP was 
textured to a mild triangular shape of the explanted leaflet 
by adding 3mm of extra patch material, as compared to 
the explanted leaflet (see Figure 2). The substitute was 
implanted using six mattress 6-0 polypropylene sutures 
following the origin of the explant line (see Figure 3). The 
last sutures on each side ended with the upper edge of the 
commissures. The aim was equal distribution on each side 
of the created base of the patch to achieve good geometry 
(see Figure 4).
After testing the valve function and successful weaning 
from CPB, one-third of the full Protamine dose was 
administered. After chest closure, echocardiography was 
Figure 1 View of the aortic valve after aortotomy showing left and 
right coronary leaflets in place whereas the tip of the forceps is 
showing the place where the non-coronary leaflet was explanted.
Figure 2 The explanted native non-coronary leaflet is used as a 
pattern for tailoring the tissue engineered patch.
Figure 3 The tissue engineered patch is implanted using single 
mattress sutures.
Figure 4 View of the aortic valve after aortotomy showing native 
left and right coronary leaflets and the implanted tissue engineered 
patch.
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Figure 5 Explanted whole aortic root after scarification of the 
animal. It shows the aortic valve with native left and right coronary 
leaflets and the implanted tissue engineered patch.
Figure 7 Postoperative echocardiographic study revealing good 
co-adaptation of the tissue engineered patch (white arrow) and the 
native aortic valve leaflet.
Figure 6 Postoperative CT study image showing co-adaptation of 
the tissue engineered patch and the native aortic valve leaflet.
Figure 8  Post-mortem analyses of the implanted tissue engineered 
patch showing blood cell infiltration into the patch (hematoxylin-
eosin stain, 400×).
done followed by computer tomography (CT). Finally, 
the sheep were sacrificed, and the whole aortic root was 
explanted (see Figure 5) and the TEP was analyzed.
Using this technique, the patch was implanted in 
nine sheep. The operation was completed successfully 
in all the nine attempts. The average aortic cross-clamp 
time was 96 minutes, with the average bypass time over 
140 minutes. Postoperative echocardiographic and CT 
studies (see Figure 6) revealed good co-adaptation of the 
leaflets (see Figure 7) without signs of relevant aortic valve 
stenosis or regurgitation. After post-operative diagnostic 
(echocardiography and CT), the animals were sacrificed 
and the TEP was analyzed. The analyses showed no tears 
within the patch due to systemic blood pressure. Histologic 
analyses showed infiltration of blood cells into the TEP (see 
Figure 8).
Only the last sheep of the series was kept alive for 24 hours 
to test feasibility for translation to chronic phase trial. 
Comments
There are increasing numbers of scientific publications on 
the use of animal models in cardiovascular disease research. 
The advantages of sheep are that they have similarities with 
humans in the molecular basis of cardiac contraction and in 
coronary anatomy. Likewise, the physiology is comparable 
to humans; especially when testing a TEP in the high 
pressure system, the mean arterial blood pressure in sheep 
seems to be of approximately 100 mmHg (26). Finally, 
calcification as one of the main outcomes might occur very 
early, as one year in a human is equivalent to seven years in 
a sheep. From our experience and set-up, we would like to 
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share some crucial issues: 
(I) Surgical access: we started with median sternotomy, 
with the idea that this approach provides the best 
exposure to the heart; however, the potential benefits of a 
thoracotomy outweighed those of sternotomy, especially 
when considering a chronic study. We believe that a 
thoracotomy leads to decreased morbidity, especially 
postoperative pain, as compared to that associated with 
sternotomy. In terms of early extubation and postoperative 
breathing (as the animals lay on the sternum), thoracotomy 
is beneficial in comparison to sternotomy. According 
to our experience, an RLT using the fourth intercostal 
space offered good exposure to the aorta and truncus 
brachiocephalicus as well as good access to the aortic valve. 
Arterial cannulation is easy to achieve using this surgical 
access. If one chooses to use a left lateral thoracotomy (LLT), 
which is possible, one has to dissect the main pulmonary 
artery to get sufficient access to the ascending aorta and the 
aortic valve. 
(II) CPB and cardioplegia: there might be several 
possibilities to perform arterial cannulation. While we tried 
to avoid femoral cannulation (lines for arterial blood pressure 
measurement and venous lines; higher infection risk), 
one of the shortcomings of right-sided thoracotomy is 
that one will not have good access to the descending aorta, 
which is a good option to cannulate when using an LLT. 
In contrast to humans, where the ascending aorta is the 
primary target, this part of the aorta in sheep is short, 
and we tried to preserve the whole ascending aorta for 
application of cardioplegia (via root) and the cross clamp as 
well as left enough material for the closure of the ascending 
aorta. Alternatively, we chose the truncus brachiocephalicus, 
which is easy to access from RLT, for arterial cannulation.
The mainstays of cardio-protection during cardiac 
surgery are cardioplegia, hypothermia, and prevention of 
cardiac distention. We always use antegrade cardioplegia 
with cannulation of the aortic root as this (still) might be 
the best way of cardiac protection through the strenuous 
CPB process. We did not actively cool the animals, but 
allowed a passive cooling down to 32 degree Celsius. To 
avoid cardiac distention, a good venous drainage for CPB is 
essential; and also the placement of the VENT catheter in 
the main pulmonary artery, which is easy to access and has 
low bleeding complications after removal might help.
(III) Technique of patch augmentation and implantation: 
the advantages of using the non-coronary leaflet seem 
to be obvious, as the risk of complications involving the 
coronary arteries are much less. We believe that in order 
to prove the hypothesis of cell immigration into the patch 
and transformation of the TEP into native leaflet tissue, 
one should cut out the whole leaflet. The explanted leaflet 
might give an idea about how big the substitute should be; 
nevertheless, we decided to add some additional space to 
the TEP to have a sufficient rim for sutures and a sufficient 
coaptation height. On the other hand, one has to be careful 
against adding too much patch material, as this might 
interfere with the function of the two remaining leaflets. 
The use of mattress suture allows a more clear view and 
better placement of the sutures as compared to a running 
suture; the thorax of sheep is deep (see Figures 1-4)! 
Our experiences and comments may help other groups 
using a sheep model in cardiovascular disease research to 
further increase animal welfare by improving their rates of 
survival.
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